During the last session, Selecta Biosciences Inc. (NASDAQ:SELB)’s traded shares were 1.11 million, with the beta value of the company hitting 1.17. At the end of the trading day, the stock’s price was $1.05, reflecting an intraday loss of -4.55% or -$0.05. The 52-week high for the SELB share is $2.73, that puts it down -160.0 from that peak though still a striking 36.19% gain since the share price plummeted to a 52-week low of $0.67. The company’s market capitalization is $152.62M, and the average intraday trading volume over the past 10 days was 0.93 million shares, and the average trade volume was 1.28 million shares over the past three months.
Selecta Biosciences Inc. (SELB) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.70. SELB has a Sell rating from 0 analyst(s) out of 7 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.08.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
Selecta Biosciences Inc. (NASDAQ:SELB) trade information
Selecta Biosciences Inc. (SELB) registered a -4.55% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -4.55% in intraday trading to $1.05 this Thursday, 05/25/23, hitting a weekly high. The stock’s 5-day price performance is -2.78%, and it has moved by -10.26% in 30 days. Based on these gigs, the overall price performance for the year is 52.04%. The short interest in Selecta Biosciences Inc. (NASDAQ:SELB) is 6.92 million shares and it means that shorts have 5.73 day(s) to cover.
The consensus price target of analysts on Wall Street is $5.14, which implies an increase of 79.57% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4.00 and $8.00 respectively. As a result, SELB is trading at a discount of -661.9% off the target high and -280.95% off the low.
Selecta Biosciences Inc. (SELB) estimates and forecasts
Statistics show that Selecta Biosciences Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Selecta Biosciences Inc. (SELB) shares have gone down -18.60% during the last six months, with a year-to-date growth rate less than the industry average at -387.50% against 11.40. Yet analysts are ramping up their growth forecast for the fiscal year 2023. Revenue is predicted to shrink -233.30% this quarter and then drop -100.00% in the quarter after that. In the rating firms’ projections, revenue will decrease -72.20% compared to the previous financial year.
Revenue for the current quarter is expected to be $11.09 million as predicted by 6 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to $6.87 million by the end of Sep 2023. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $39.27 million and $25.21 million respectively. In this case, analysts expect current quarter sales to shrink by -71.80% and then drop by -72.70% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 15.70%. While earnings are projected to return 207.90% in 2023.
SELB Dividends
Selecta Biosciences Inc. is due to release its next quarterly earnings between August 02 and August 07. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Selecta Biosciences Inc. (NASDAQ:SELB)’s Major holders
Selecta Biosciences Inc. insiders own 25.48% of total outstanding shares while institutional holders control 45.86%, with the float percentage being 61.54%. Vanguard Group, Inc. (The) is the largest shareholder of the company, while 112 institutions own stock in it. As of Mar 30, 2023, the company held over 6.62 million shares (or 4.31% of all shares), a total value of $9.2 million in shares.
The next largest institutional holding, with 4.88 million shares, is of Artal Group S.A.’s that is approximately 3.18% of outstanding shares. At the market price on Mar 30, 2023, these shares were valued at $6.79 million.
Also, the Mutual Funds coming in first place with the largest holdings of Selecta Biosciences Inc. (SELB) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Dec 30, 2022 indicates that Vanguard Total Stock Market Index Fund owns about 3.45 million shares. This amounts to just over 2.25 percent of the company’s overall shares, with a $3.89 million market value. The same data shows that the other fund manager holds slightly less at 1.75 million, or about 1.14% of the stock, which is worth about $1.97 million.
